Abstract
C25H30FN3O9, monoclinic, P21/n, a = 16.3585(4) Å, b = 7.8763(2) Å, c = 18.7735(4) Å, ꞵ = 90.5690(10)°, V = 2418.74(10) Å3, Z = 4, Rgt (F) = 0.0410, wR ref (F2) = 0.1055, T = 170 K.
The molecular structure is shown in the figure. Table 1 contains the crystallographic data. The list of the atoms including atomic coordinates and displacement parameters can be found in the cif-file attached to this article.

Data collection and handling.
| Crystal: | Colourless block |
| Size | 0.42 × 0.20 × 0.15 mm |
| Wavelength: | Mo Kα radiation (0.71073 Å) |
| μ: | 0.12 mm−1 |
| Diffractometer, scan mode: | Bruker D8 Venture, φ and ω scans |
| θmax, completeness: | 28.3°, 100 % |
| N(hkl)measured, N(hkl)unique, Rint: | 42,141, 5,967, 0.038 |
| Criterion for Iobs, N(hkl)gt: | Iobs > 2 σ(Iobs), 5094 |
| N(param)refined: | 351 |
| Programs: | Bruker, 1 Olex2, 2 SHELX 3 , 4 |
1 Source of materials
Equimolar quantities of norfloxacin (0.032 g) and syringic acid (0.020 g) in a 10 mL glass vial. The solid mixture was subsequently treated with a binary solvent system consisting of deionized water (2 mL) and absolute ethanol (2 mL). The mixture was transferred to a temperature -controlled magnetic stirring apparatus and gradually heated to 30 °C under gentle agitation (200 rpm) until complete dissolution was achieved. Through controlled solvent evaporation, the system was maintained in a metastable supersaturated state for 24 h to facilitate crystal nucleation and growth. The resulting suspension was vacuum-filtered through a Büchner funnel to isolate the crystalline product. The obtained compound was characterized as 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate.
2 Experimental details
Absorption corrections were applied by using multi-scan program. 1 Using Olex2, 2 the structure was solved with the ShelXT 3 structure solution program using Intrinsic Phasing and refined with the ShelXL 4 refinement package using Least Squares minimisation. The H atoms were fixed, fixed Uiso were set to 1.2 times of all C(H) groups, C(H,H) groups and N(H,H) groups; 1.5 times of C(H,H,H,H) groups, O(H) groups and O(H,H) groups.
3 Comment
Norfloxacin, a fluoroquinolone antibacterial agent, is widely employed in treating infections caused by Gram-positive and Gram-negative bacteria. 5 Like other fluoroquinolones, its aqueous solubility exhibits a pronounced pH-dependent profile due to zwitterion formation via proton transfer between the carboxylic acid group and the basic piperazine ring. 6 At physiological pH, norfloxacin suffers from limited solubility and poor permeability, classifying it as a Biopharmaceutics Classification System (BCS) Class IV drug with inherently low bioavailability. 7 To address these limitations, pharmaceutical salt/cocrystal engineering has emerged as a strategic approach, wherein pairing the drug with a pharmaceutically acceptable counterion can modulate its physicochemical properties. 8 Previous studies have demonstrated the efficacy of salt formation with organic acids in enhancing norfloxacin’s solubility and dissolution performance. 9 , 10 , 11 In this study, we successfully designed, synthesized, and structurally characterized a novel norfloxacin-syringic acid salt. The asymmetric unit of the crystal structure [norfloxacin⋯syringic acid⋯H2O] comprises one norfloxacin cation, one syringic acid anion, and one water molecule. Key structural features include: A classical N–H⋯O hydro gen bond formed between the N1H1A moiety of the piperazine group and the O4 oxygen atom of syringic acid. Hydration-mediated interactions where the O9–H9A group of water forms hydrogen bonds with the O5 oxygen atom of syringic acid. The crystal packing exhibits a distinctive two-fold screw symmetry along the [0 1 0] axis, with screw components positioned at (¼, y, ¼). This symmetry element contributes to the three dimensional network formation through systematic molecular repetition.
Acknowledgments
We would also like to thank Mr Jiyong Liu from the Chemistry Instrumentation Center Zhejiang University for X-ray crystallographic analysis.
References
1. Bruker. Apex3 v. 2016.9–0 and SAINT v. 8.37A; Bruker Axs Inc.: Madison, Wisconsin, USA, 2016.Search in Google Scholar
2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. J. Appl. Cryst. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar
3. Sheldrick, G. M. SHELXT – Integrated Space-Group and Crystal-Structure Determination. Acta Crystallogr. 2015, A71, 3–8; https://doi.org/10.1107/s2053273314026370.Search in Google Scholar PubMed PubMed Central
4. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar
5. Sun, Y. Y.; Gu, Z. N.; Jiang, C. J. The Crystal Structure of 4-(3-Carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium-2-Carboxy-6-Nitrobenzoate Monohydrate, C24H25FN4O10. Z. Kristalllogr. N. Cryst. Struct. 2024, 239, 865–867; https://doi.org/10.1515/ncrs-2024-0203.Search in Google Scholar
6. Lin, S.; Lou, C.; Jiang, C. J. The Crystal Structure of 4-(3-carboxy-1-Cyclopropyl-6-fluoro-8-methoxy-4-Oxo-1,4-dihydroquinolin-7-yl)-2-methylpiperazin-1-ium 2,5-Dihydroxybenzoate Methanol Solvate, C27H32FN3O9. Z. Kristalllogr. N. Cryst. Struct. 2023, 238 (5), 841–843; https://doi.org/10.1515/ncrs-2023-0228.Search in Google Scholar
7. Guo, X.; Zhao, P.; Jiang, C.; Ma, Y.; Miao, M. Atmospheric Oxygen Mediated Oxidation Coupling of Primary and Secondary Alcohols: Synthesis of Pyrazolo[1,5-a] Pyrimidines. Org. Biomol. Chem. 2025, 23, 2092–2095; https://doi.org/10.1039/D4OB02045F.Search in Google Scholar PubMed
8. Basavoju, S.; Boström, D.; Velaga, S. P. Pharmaceutical Cocrystal and Salts of Norfloxacin. Cryst. Growth Des. 2006, 6, 2699–2708.10.1021/cg060327xSearch in Google Scholar
9. O′ Malley, C.; McArdle, P.; Erxleben, A. Formation of Salts and Molecular Ionic Cocrystals of Fluoroquinolones and α,ω-dicarboxylic Acids. Cryst. Growth Des. 2022, 22 (5), 3060–3071; https://doi.org/10.1021/acs.cgd.1c01509.Search in Google Scholar PubMed PubMed Central
10. Gunnam, A.; Nangia, A. K. Novel Hydrate and Anhydrate Cocrystals/Salts of Norfloxacin and Their Physicochemical Properties. Cryst. Growth Des. 2023, 23 (6), 4198–4213; https://doi.org/10.1021/acs.cgd.3c00023.Search in Google Scholar
11. Liang, D.; Li, F.; Duan, J.; Sun, W.; Yu, X. Two Novel Hydrate Salts of Norfloxacin with Phenolic Acids and their Physicochemical Properties. Antibiotics 2024, 13 (9), 888–900; https://doi.org/10.3390/antibiotics13090888.Search in Google Scholar PubMed PubMed Central
© 2025 the author(s), published by De Gruyter, Berlin/Boston
This work is licensed under the Creative Commons Attribution 4.0 International License.
Articles in the same Issue
- Frontmatter
- New Crystal Structures
- Crystal structure of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bi(1,3,4-oxadiazole), C16H4N10O14
- Crystal structure of catena-poly[(μ3-4,4′-oxydibenzoato- κ5 O,O′: O″,O‴:O‴)-bis(2,4,6-tri(3-pyridine)-1,3,5-triazine-κ1 N)cadmium(II)], C50H32CdN12O5
- The crystal structure of 1,4-diazepane-1,4-diium potassium trinitrate, C5H14KN5O9
- The crystal structure of benzyl 2,2,5,5-tetramethylthiazolidine-4-carboxylate, C15H21NO2S
- Crystal structure of 2-hydroxyethyl-triphenylphosphonium tetracyanidoborate, C24H20BN4OP
- The crystal structure of 1-methyl-3-(N-methylnitrous amide–N-methylene) imidazolidine-2,4,5-trione
- Crystal structure of N-((3-cyano-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-(2,2,2-trifluoroacetyl)-1H-pyrazol-5-yl)carbamoyl)-2,6-difluorobenzamide, C20H7Cl2F8N5O3S
- Crystal structure of 5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a] isoquinolin-6(5H)-one, C20H18F2N2O
- The crystal structure of N′,N″-[1,2-bis(4-chlorophenyl)ethane-1,2-diylidene]bis(furan-2- carbohydrazide), C24H16Cl2N4O4
- Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromoantimony(III), [C25H21BrP]+[SbBr4]−
- Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromidoindium(III), [C25H21BrP]+[InBr4]−
- The crystal structure of 4-carboxy-2-oxobutan-1-aminium chloride, C5H10ClNO3
- Crystal structure of (4-(4-chlorophenyl)-1H-pyrrole-3-carbonyl)ferrocene, C21H16ClFeNO
- The crystal structure of dichlorido(η6-p-cymene)(triphenylarsine)ruthenium(II), C28H29AsCl2Ru
- Crystal structure of (Z)-2-hydroxy-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H16N2O2
- The crystal structure of 10-(1-bromoethyl)-14-(bromomethyl)dibenzo[a, c]acridine, C24H17NBr2
- Synthesis and crystal structure of 6-methoxy-7-[(4-methoxyphenyl)methoxy]-2H-1-benzopyran-2-one, C18H16O5
- Synthesis and crystal structure of ethyl 4-((4-trifluoromethylbenzyl)amino)benzo, C17H16F3NO2
- The crystal structure of (Z)-2-(tert-butyl)-6-(7-(tert-butyl)-5-methylbenzo[d][1,3]oxathiol-2-ylidene)-4-methylcyclohexa-2,4-dien-1-one, C23H28O2S
- The crystal structure of (R)-2-aminobutanamide hydrochloride, C4H11ClN2O
- Crystal structure of bromido[hydridotris(3-tert-butyl-5-isopropylpyrazolyl)borato-κ3 N,N′,N″]copper(II), C30H52BBrCuN6
- Crystal structure of chlorido{hydridotris[3-mesityl-5-methyl-1H-pyrazol-1-yl-κN3]borato}-copper(II) dichloromethane monosolvate
- Crystal structure of 4-[3,5-bis(propan-2-yl)-1H-pyrazol-4-yl]pyridine, C14H19N3
- Crystal structure of ((4-(4-bromophenyl)-1H-pyrrol-3-yl)methyl)ferrocene, C21H16BrFeNO
- Crystal structure of [(4-chlorobenzyl)triphenylphosphonium] dichloridocopper(I), {[C25H21ClP]+[CuCl2]−}n
- The crystal structure of {Cu(2,9-diisopropyl-4,7-diphenyl-1,10-phenanthroline)[4,5-bis(diphenylphosphino)-9,9-dimethylxanthene]}+ PF6−·1.5(EtOAC)
- Crystal structure of 3,5-bis(t-butyl)-1H-pyrazol-4-amine, C11H21N3
- Crystal structure of [(2,4-dichlorobenzyl)triphenylphosphonium] trichloridocopper(II), [C25H20Cl2P]+[CuCl3]−
- The crystal structure of dipotassium sulfide, K2S
- Crystal structure of (4-(4-methoxyphenyl)-1H-pyrrole-3-carbonyl)ferrocene, C22H19FeNO2
- Crystal structure of (E)-6-(4-methylpiperazin-1-yl)-2-(4-(trifluoromethyl)benzylidene)-3, 4-dihydronaphthalen-1(2H)-one, C23H23F3N2O
- Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
- Crystal structure of Ce9Ir37Ge25
- The crystal structure of ethyl 6-(2-nitrophenyl)imidazo[2,1-b]thiazole-3-carboxylate, C14H11N3O4S
- Crystal structure of (4-(4-isopropylphenyl)-1H-pyrrol-3-yl)(ferrocenyl)methanone, C24H23FeNO
- Crystal structure of bis(methylammonium) tetrathiotungstate(VI), (CH3NH3)2[WS4]
- Crystal structure of 6,11-dihydro-12H-benzo[e]indeno[1,2-b]oxepin-12-one, C17H12O2
- Crystal structure of 3-[(4-phenylpiperidin-1-yl)methyl]-5-(thiophen-2-yl)-2,3-dihydro-1,3,4- oxadiazole-2-thione, C18H19N3OS2
- Crystal structure of N-isopropyl-1,8-naphthalimide C15H13NO2
- TiNiSi-type EuPdBi
- Crystal structure of 1-(p-tolylphenyl)-4-(2-thienoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O2S
- The crystal structure of 3-(3-carboxypropyl)-2-nitro-1H-pyrrole 1-oxide, C7H9N3O5
- The crystal structure of tetraaqua-bis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k2O:N)-tetrakis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k1N)trizinc(II) hexahydrate C36H52N18O32Zn3
- The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C25H30FN3O9
- Crystal structure of bis(DL-1-carboxy-2-(1H-indol-3-yl)ethan-1-aminium) oxalate — acetic acid (1/2)
- Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
- The crystal structure of actarit, C10H11NO3
- The crystal structure of bicyclol, C19H18O9
- The crystal structure of topiroxostat, C13H8N6
- Crystal structure of 2,2-dichloro-N-methyl-N-(4-p-tolylthiazol-2-yl)acetamide, C13H12Cl2N2OS
- Crystal structure of 4-(trifluoromethyl)-7-coumarinyl trifluoromethanesulfonate C11H4F6O5S
- Crystal structure of (1,4,7,10,13,16-hexaoxacyclooctadecane-κ6O6)-((Z)-N,N′-bis(2-(dimethylamino)phenyl)carbamimidato-κ1N)potassium(I)
- Crystal structure of (Z)-2-(5-((4-(dimethylamino)naphthalen-1-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, C18H16N2O3S2
- Crystal structure of (4-fluorobenzyl)triphenylphosphonium bromide, C25H21BrFP
- The crystal structure of dichlorido-[6-(pyridin-2-yl)phenanthridine-κ2N, N′]zinc(II)-chloroform (1/1), C19H13N2ZnCl5
- Crystal structure of (E)-(3-(2,4-dichlorophenyl)acryloyl)ferrocene, C19H14Cl2FeO
- The crystal structure of (E)-7-chloro-1-cyclopropyl-6-fluoro-3-((2-hydroxybenzylidene)amino)quinolin-4(1H)-one, C19H14ClFN2O2
- Crystal structure of 2-bromo-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13BrFNO4S2
- Crystal structure of 2-chloro-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13ClFNO4S2
- Crystal structure of 5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile, C20H15F2N3O
Articles in the same Issue
- Frontmatter
- New Crystal Structures
- Crystal structure of 5,5′-bis(2,4,6-trinitrophenyl)-2,2′-bi(1,3,4-oxadiazole), C16H4N10O14
- Crystal structure of catena-poly[(μ3-4,4′-oxydibenzoato- κ5 O,O′: O″,O‴:O‴)-bis(2,4,6-tri(3-pyridine)-1,3,5-triazine-κ1 N)cadmium(II)], C50H32CdN12O5
- The crystal structure of 1,4-diazepane-1,4-diium potassium trinitrate, C5H14KN5O9
- The crystal structure of benzyl 2,2,5,5-tetramethylthiazolidine-4-carboxylate, C15H21NO2S
- Crystal structure of 2-hydroxyethyl-triphenylphosphonium tetracyanidoborate, C24H20BN4OP
- The crystal structure of 1-methyl-3-(N-methylnitrous amide–N-methylene) imidazolidine-2,4,5-trione
- Crystal structure of N-((3-cyano-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-(2,2,2-trifluoroacetyl)-1H-pyrazol-5-yl)carbamoyl)-2,6-difluorobenzamide, C20H7Cl2F8N5O3S
- Crystal structure of 5-(2,2-difluoropropyl)-5-methylbenzo[4,5]imidazo[2,1-a] isoquinolin-6(5H)-one, C20H18F2N2O
- The crystal structure of N′,N″-[1,2-bis(4-chlorophenyl)ethane-1,2-diylidene]bis(furan-2- carbohydrazide), C24H16Cl2N4O4
- Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromoantimony(III), [C25H21BrP]+[SbBr4]−
- Crystal structure of [(4-bromobenzyl)triphenylphosphonium] tetrabromidoindium(III), [C25H21BrP]+[InBr4]−
- The crystal structure of 4-carboxy-2-oxobutan-1-aminium chloride, C5H10ClNO3
- Crystal structure of (4-(4-chlorophenyl)-1H-pyrrole-3-carbonyl)ferrocene, C21H16ClFeNO
- The crystal structure of dichlorido(η6-p-cymene)(triphenylarsine)ruthenium(II), C28H29AsCl2Ru
- Crystal structure of (Z)-2-hydroxy-N′-(1-(o-tolyl)ethylidene)benzohydrazide, C16H16N2O2
- The crystal structure of 10-(1-bromoethyl)-14-(bromomethyl)dibenzo[a, c]acridine, C24H17NBr2
- Synthesis and crystal structure of 6-methoxy-7-[(4-methoxyphenyl)methoxy]-2H-1-benzopyran-2-one, C18H16O5
- Synthesis and crystal structure of ethyl 4-((4-trifluoromethylbenzyl)amino)benzo, C17H16F3NO2
- The crystal structure of (Z)-2-(tert-butyl)-6-(7-(tert-butyl)-5-methylbenzo[d][1,3]oxathiol-2-ylidene)-4-methylcyclohexa-2,4-dien-1-one, C23H28O2S
- The crystal structure of (R)-2-aminobutanamide hydrochloride, C4H11ClN2O
- Crystal structure of bromido[hydridotris(3-tert-butyl-5-isopropylpyrazolyl)borato-κ3 N,N′,N″]copper(II), C30H52BBrCuN6
- Crystal structure of chlorido{hydridotris[3-mesityl-5-methyl-1H-pyrazol-1-yl-κN3]borato}-copper(II) dichloromethane monosolvate
- Crystal structure of 4-[3,5-bis(propan-2-yl)-1H-pyrazol-4-yl]pyridine, C14H19N3
- Crystal structure of ((4-(4-bromophenyl)-1H-pyrrol-3-yl)methyl)ferrocene, C21H16BrFeNO
- Crystal structure of [(4-chlorobenzyl)triphenylphosphonium] dichloridocopper(I), {[C25H21ClP]+[CuCl2]−}n
- The crystal structure of {Cu(2,9-diisopropyl-4,7-diphenyl-1,10-phenanthroline)[4,5-bis(diphenylphosphino)-9,9-dimethylxanthene]}+ PF6−·1.5(EtOAC)
- Crystal structure of 3,5-bis(t-butyl)-1H-pyrazol-4-amine, C11H21N3
- Crystal structure of [(2,4-dichlorobenzyl)triphenylphosphonium] trichloridocopper(II), [C25H20Cl2P]+[CuCl3]−
- The crystal structure of dipotassium sulfide, K2S
- Crystal structure of (4-(4-methoxyphenyl)-1H-pyrrole-3-carbonyl)ferrocene, C22H19FeNO2
- Crystal structure of (E)-6-(4-methylpiperazin-1-yl)-2-(4-(trifluoromethyl)benzylidene)-3, 4-dihydronaphthalen-1(2H)-one, C23H23F3N2O
- Crystal structure of (E)-6-morpholino-2-(4-(trifluoromethyl)benzylidene)-3,4-dihydronaphthalen-1(2H)-one, C22H20F3NO2
- Crystal structure of Ce9Ir37Ge25
- The crystal structure of ethyl 6-(2-nitrophenyl)imidazo[2,1-b]thiazole-3-carboxylate, C14H11N3O4S
- Crystal structure of (4-(4-isopropylphenyl)-1H-pyrrol-3-yl)(ferrocenyl)methanone, C24H23FeNO
- Crystal structure of bis(methylammonium) tetrathiotungstate(VI), (CH3NH3)2[WS4]
- Crystal structure of 6,11-dihydro-12H-benzo[e]indeno[1,2-b]oxepin-12-one, C17H12O2
- Crystal structure of 3-[(4-phenylpiperidin-1-yl)methyl]-5-(thiophen-2-yl)-2,3-dihydro-1,3,4- oxadiazole-2-thione, C18H19N3OS2
- Crystal structure of N-isopropyl-1,8-naphthalimide C15H13NO2
- TiNiSi-type EuPdBi
- Crystal structure of 1-(p-tolylphenyl)-4-(2-thienoyl)-3-methyl-1H-pyrazol-5-ol, C16H14N2O2S
- The crystal structure of 3-(3-carboxypropyl)-2-nitro-1H-pyrrole 1-oxide, C7H9N3O5
- The crystal structure of tetraaqua-bis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k2O:N)-tetrakis(2-(2-methyl-5-nitro-1H-imidazol-1-yl)acetato-k1N)trizinc(II) hexahydrate C36H52N18O32Zn3
- The crystal structure of 4-(3-carboxy-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinolin-7-yl)piperazin-1-ium 4-hydroxy-3,5-dimethoxybenzoate monohydrate, C25H30FN3O9
- Crystal structure of bis(DL-1-carboxy-2-(1H-indol-3-yl)ethan-1-aminium) oxalate — acetic acid (1/2)
- Crystal structure of methyl (E)-4-((4-methylphenyl)sulfonamido)but-2-enoate, C12H15NO4S
- The crystal structure of actarit, C10H11NO3
- The crystal structure of bicyclol, C19H18O9
- The crystal structure of topiroxostat, C13H8N6
- Crystal structure of 2,2-dichloro-N-methyl-N-(4-p-tolylthiazol-2-yl)acetamide, C13H12Cl2N2OS
- Crystal structure of 4-(trifluoromethyl)-7-coumarinyl trifluoromethanesulfonate C11H4F6O5S
- Crystal structure of (1,4,7,10,13,16-hexaoxacyclooctadecane-κ6O6)-((Z)-N,N′-bis(2-(dimethylamino)phenyl)carbamimidato-κ1N)potassium(I)
- Crystal structure of (Z)-2-(5-((4-(dimethylamino)naphthalen-1-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid, C18H16N2O3S2
- Crystal structure of (4-fluorobenzyl)triphenylphosphonium bromide, C25H21BrFP
- The crystal structure of dichlorido-[6-(pyridin-2-yl)phenanthridine-κ2N, N′]zinc(II)-chloroform (1/1), C19H13N2ZnCl5
- Crystal structure of (E)-(3-(2,4-dichlorophenyl)acryloyl)ferrocene, C19H14Cl2FeO
- The crystal structure of (E)-7-chloro-1-cyclopropyl-6-fluoro-3-((2-hydroxybenzylidene)amino)quinolin-4(1H)-one, C19H14ClFN2O2
- Crystal structure of 2-bromo-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13BrFNO4S2
- Crystal structure of 2-chloro-11-(((fluoromethyl)sulfonyl)methyl)-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide, C16H13ClFNO4S2
- Crystal structure of 5-(2,2-difluoropropyl)-5-methyl-6-oxo-5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline-3-carbonitrile, C20H15F2N3O